Drug Trial Radar · NCT05126758
A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
106
Actual
Start
Jun 22, 2022
Primary completion
Jun 18, 2025
Study completion Mar 2027
Sponsor
- Lead sponsor
- Capricor Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 19, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either deramiocel or placebo every 3 months for a total of 4 doses during the first 12 months of the study. All participants will be eligible to receive 4 doses of deramiocel for an additional 12 months as part of an open-label extended assessment period. After completion of the first open-label extension (Months 12-24), subjects who have completed Month 24 are eligible to continue onto a Long-Term Open-Label Extension period that will provide treatment with deramiocel until commercial availability, or until sponsor's decision to terminate the trial, or the participant withdraws consent.
Conditions
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Muscular Disorders, Atrophic
- Muscular Diseases
- Neuromuscular Diseases
- Genetic Diseases, X-Linked
- Genetic Diseases, Inborn
- Nervous System Diseases
Interventions
DeramiocelBiological
Cardiosphere-Derived Cells (CDCs)
PlaceboBiological
Placebo
Cardiac magnetic resonance imagingDiagnostic test
Cardiac magnetic resonance imaging is performed to assess cardiac function
Cardiac magnetic resonance imaging with contrastDiagnostic test
Cardiac magnetic resonance imaging with contrast to assess late gadolinium enhancement (LGE) in Cohort B participants
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in the upper limb functionTime frame: At Month 12
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona
Arkansas Children's Hospital
Little Rock, Arkansas
UCSD Altman Clinical and Translational Research Institute
La Jolla, California
Children's Hospital of Los Angeles, Division of Neurology
Los Angeles, California
University of California, Davis
Sacramento, California
Children's Hospital Colorado
Aurora, Colorado
Rare Disease Research, LLC
Atlanta, Georgia
Ann & Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Iowa Hospitals and Clinics
Iowa City, Iowa
Boston Children's Hospital
Boston, Massachusetts
University of Missouri Health Care
Columbia, Missouri
Saint Louis Children's Hospital
St Louis, Missouri
Rare Disease Research NC LLC
Hillsborough, North Carolina
Akron Children's Hospital
Akron, Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Children's Health Specialty Care Pavilion
Dallas, Texas
University of Utah Hospital
Salt Lake City, Utah
University of Virginia Children's Hospital
Charlottesville, Virginia
Seattle Children's
Seattle, Washington
Children's Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.